Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome

Nature Medicine

Volumn 2, Issue 1, 1996, Pages 93-95

  Teller, Jan K ^a   Russo, Claudio ^a   DeBusk, Laura M ^a   Angelini, Giovanna ^b   Zaccheo, Damiano ^c   Dagna Bricarelli, Francesca ^d   Scartezzini, Pietro ^d   Bertolini, Stefano ^e   Mann, David M A ^f   Tabaton, Massimo ^c   Gambetti, Pierluigi ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ADVANCED BIOTECHNOLOGY CENTER   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; PRIMER DNA; AMYLOID PRECURSOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; BRAIN; BRAIN CORTEX; CHILD; DOWN SYNDROME; FETUS; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NEWBORN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRENATAL DEVELOPMENT; PRESCHOOL CHILD; SOLUBILITY; WESTERN BLOTTING; ALZHEIMER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN TISSUE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMYLOID; AMYLOID BETA-PROTEIN; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; CEREBRAL CORTEX; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; DOWN SYNDROME; FETUS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SOLUBILITY;

EID: 13344293701     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0196-93     Document Type: Article

References (23)

1. Selkoe, D.J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373-403 (1994).
2. Selkoe, D.J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17, 489-517 (1994).
3. Cai, X.-D., Golde, T.E. & Younkin S.G. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259, 514-516 (1993).
4. Citron, M. et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674 (1992).
5. Suzuki, N, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 264, 1336-1340 (1994).
6. Wisniewski, K.E., Wisniewski, H.M. & Wen, G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17, 278-282 (1985).
7. Mann, D.M.A., Yuonis, N., Jones, D. & Stoddart, R.W. The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4. Neurodegeneration 1, 201-215 (1992).
8. Iwatsubo, T., Mann, D.M.A., Odaka, A., Suzuki, N. & Ihara, Y. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann. Neurol. 37, 294-299 (1995).
9. Tamaoka, A. et al. Biochemical evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem. Biophys. Res. Commun. 205, 834-842 (1994).
10. Tabaton, M, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 200, 1598-1603 (1994).
11. Roberts, G.W., Gentleman, S.M., Lynch, A. & Graham, D.I. Beta A4 amyloid protein deposition in brain after head trauma. Lancet ii, 1422-1423 (1991).
12. Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C. & Suzuki, N. Long amyloid β-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 34, 10272-10278 (1995).
13. Rumble, B. et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Eng. J. Med. 320, 1446-1452 (1989).
14. Hilbich, C. et al. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J. Mol. Biol. 218, 149-163 (1991).
15. Gravina, S.A. et al. Amyloid β protein (Aβ) in Alzheimer's disease brain: Biochemical and immunocytochemical analysis with antibodies specific for forms at Aβ40 or Aβ42(43). J. Biol. Chem. 270, 7013-7016 (1995).
16. Tamaoka, A. et al. Amyloid β protein 1-42/43 (Aβ 1-42/43) in cerebellar diffuse plaques: Enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 679, 151-156 (1995).
17. Yamaguchi, H., Sugihara, S., Ishiguro, K, Takashima, A. & Hirai, S. Immunohistochemical analysis of COOH-termini of amyloid beta protein (Aβ) using end-specific antisera for Aβ40 and Aβ42 in Alzheimer's disease and normal aging. Amyloid: Int. J. Exp. Clin. Invest. 2, 7-16 (1995).
18. Wenham, P.R., Price, W.H. & Blundell, G. Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158-1159 (1991).
19. Schägger, H. & von Jagow, G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166, 368-379 (1987).
20. Kim, K.S. et al. Detection and quantification of amyloid β-peptide with 2 monoclonal antibodies. Neurosci. Res. Commun. 7, 113-122 (1990).
21. Kim, K.S. et al. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci. Res. Commun. 2, 121-130 (1988).
22. Sternberger, L.A. Immunocytochemistry (Wiley, New York, 1979).
23. Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159 (1987).